GlobeNewswire: Loxo Oncology, Inc. Contains the last 10 of 128 releaseshttp://www.globenewswire.com/External?Length=42024-03-30T05:50:37ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/02/01/1709077/0/en/Lilly-and-Loxo-Oncology-Announce-Expiration-of-HSR-Act-Waiting-Period-in-Connection-with-Proposed-Transaction.html?f=22&fvtc=4&fvtv=22624Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction2019-02-01T11:45:00Z<![CDATA[INDIANAPOLIS and STAMFORD, CT, Feb. 01, 2019 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY) (“Lilly”) and Loxo Oncology, Inc. (NASDAQ: LOXO) (“Loxo Oncology”) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Lilly’s previously-announced tender offer to acquire all outstanding shares of Loxo Oncology for a purchase price of $235.00 per share in cash (the “Offer Price”), or approximately $8.0 billion.]]>https://www.globenewswire.com/news-release/2019/01/07/1681072/0/en/Lilly-Announces-Agreement-To-Acquire-Loxo-Oncology.html?f=22&fvtc=4&fvtv=22624Lilly Announces Agreement To Acquire Loxo Oncology2019-01-07T11:30:00Z<![CDATA[INDIANAPOLIS and STAMFORD, Conn., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY) and Loxo Oncology, Inc. (NASDAQ: LOXO) today announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion. Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers.]]>https://www.globenewswire.com/news-release/2018/12/21/1677574/0/en/Loxo-Oncology-Announces-Initiation-of-Phase-1-2-Clinical-Trial-for-Highly-Selective-Non-Covalent-BTK-Inhibitor-LOXO-305.html?f=22&fvtc=4&fvtv=22624Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-3052018-12-21T11:45:00Z<![CDATA[STAMFORD, Conn., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers, today announced that it has initiated a Phase 1/2 clinical trial of LOXO-305. LOXO-305 is an investigational, highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor specifically designed to address acquired resistance and intolerance in patients previously treated with FDA-approved BTK inhibitors.]]>https://www.globenewswire.com/news-release/2018/11/27/1657077/0/en/FDA-Approves-Vitrakvi-larotrectinib-the-First-Ever-TRK-Inhibitor-for-Patients-with-Advanced-Solid-Tumors-Harboring-an-NTRK-Gene-Fusion-1-2.html?f=22&fvtc=4&fvtv=22624FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)2018-11-27T00:16:37Z<![CDATA[STAMFORD, Conn. and WHIPPANY, N.J., Nov. 26, 2018 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) today approved Vitrakvi® (larotrectinib), the first ever oral TRK inhibitor, for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.1,2 This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Vitrakvi is the first treatment to receive a tumor-agnostic indication at the time of initial FDA approval. In clinical trials of patients with TRK fusion cancer, Vitrakvi demonstrated an ORR of 75 percent (N=55) (95% CI, 61%, 85%), including a 22 percent complete response (CR) rate.2]]>https://www.globenewswire.com/news-release/2018/11/08/1647770/0/en/Loxo-Oncology-Reports-Third-Quarter-2018-Financial-Results.html?f=22&fvtc=4&fvtv=22624Loxo Oncology Reports Third Quarter 2018 Financial Results2018-11-08T11:45:00Z<![CDATA[Larotrectinib New Drug Application (NDA) PDUFA date is November 26, 2018]]>https://www.globenewswire.com/news-release/2018/11/06/1645824/0/en/Loxo-Oncology-to-Participate-in-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=22624Loxo Oncology to Participate in Upcoming Investor Conferences2018-11-06T11:45:00Z<![CDATA[STAMFORD, Conn., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, today announced that company management will participate in fireside chats at the following upcoming investor conferences:]]>https://www.globenewswire.com/news-release/2018/11/01/1640908/0/en/Loxo-Oncology-to-Announce-Third-Quarter-2018-Financial-Results.html?f=22&fvtc=4&fvtv=22624Loxo Oncology to Announce Third Quarter 2018 Financial Results2018-11-01T10:45:00Z<![CDATA[STAMFORD, Conn., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, will announce financial results for the third quarter ended September 30, 2018 on November 8, 2018 before the Nasdaq market open. At 8:00 a.m. ET that day, Loxo Oncology management will host a conference call to discuss these financial results, in addition to recent updates on development and corporate activities.]]>https://www.globenewswire.com/news-release/2018/10/21/1624355/0/en/Loxo-Oncology-Announces-Larotrectinib-Clinical-Update-in-Patients-with-TRK-Fusion-Cancers-at-the-European-Society-for-Medical-Oncology-2018-Congress.html?f=22&fvtc=4&fvtv=22624Loxo Oncology Announces Larotrectinib Clinical Update in Patients with TRK Fusion Cancers at the European Society for Medical Oncology 2018 Congress2018-10-21T09:12:00Z<![CDATA[- Median Duration of Response Not Reached With One Year of Additional Follow-up -]]>https://www.globenewswire.com/news-release/2018/10/15/1621029/0/en/Loxo-Oncology-Announces-Receipt-of-Breakthrough-Therapy-Designation-from-U-S-Food-and-Drug-Administration-for-LOXO-292-for-the-Treatment-of-RET-Fusion-Positive-Thyroid-Cancer.html?f=22&fvtc=4&fvtv=22624Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid Cancer2018-10-15T10:45:00Z<![CDATA[STAMFORD, Conn., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to LOXO-292, a selective RET inhibitor, for the treatment of patients with advanced RET fusion-positive thyroid cancer who require systemic therapy, have progressed following prior treatment and have no acceptable alternative treatment options. This designation supplements the two LOXO-292 Breakthrough Therapy Designations granted in September 2018. The Breakthrough Therapy Designation announced today was also based on data from the ongoing global Phase 1/2 LIBRETTO-001 clinical trial.]]>https://www.globenewswire.com/news-release/2018/10/09/1618335/0/en/Loxo-Oncology-Announces-Details-for-Data-Presentations-at-the-European-Society-for-Medical-Oncology-2018-Congress.html?f=22&fvtc=4&fvtv=22624Loxo Oncology Announces Details for Data Presentations at the European Society for Medical Oncology 2018 Congress2018-10-09T10:45:00Z<![CDATA[STAMFORD, Conn., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, today announced that investigators will present data from the larotrectinib and LOXO-292 programs at the European Society for Medical Oncology (ESMO) 2018 Congress to be held October 19-23, 2018, in Munich, Germany.]]>